238 related articles for article (PubMed ID: 20006625)
41. Bortezomib resistance in a myeloma cell line is associated to PSMβ5 overexpression and polyploidy.
Balsas P; Galán-Malo P; Marzo I; Naval J
Leuk Res; 2012 Feb; 36(2):212-8. PubMed ID: 21978467
[TBL] [Abstract][Full Text] [Related]
42. Proteasome inhibitor bortezomib increases radiation sensitivity in androgen independent human prostate cancer cells.
Goktas S; Baran Y; Ural AU; Yazici S; Aydur E; Basal S; Avcu F; Pekel A; Dirican B; Beyzadeoglu M
Urology; 2010 Apr; 75(4):793-8. PubMed ID: 19800672
[TBL] [Abstract][Full Text] [Related]
43. Bortezomib inhibits proteasomal degradation of IκBα and induces mitochondrial dependent apoptosis in activated B-cell diffuse large B-cell lymphoma.
Bu R; Hussain AR; Al-Obaisi KA; Ahmed M; Uddin S; Al-Kuraya KS
Leuk Lymphoma; 2014 Feb; 55(2):415-24. PubMed ID: 23697845
[TBL] [Abstract][Full Text] [Related]
44. Bortezomib therapeutic effect is associated with expression and mutation of FGFR3 in human lymphoma cells.
Zheng W; Guan M; Zhu L; Cai Z; Chung V; Huang H; Yen Y
Anticancer Res; 2010 Jun; 30(6):1921-30. PubMed ID: 20651335
[TBL] [Abstract][Full Text] [Related]
45. Cloning and characterization of the promoter region of human focal adhesion kinase gene: nuclear factor kappa B and p53 binding sites.
Golubovskaya V; Kaur A; Cance W
Biochim Biophys Acta; 2004 May; 1678(2-3):111-25. PubMed ID: 15157737
[TBL] [Abstract][Full Text] [Related]
46. Bortezomib suppresses the growth of leukemia cells with Notch1 overexpression in vivo and in vitro.
Huang C; Hu X; Wang L; Lü S; Cheng H; Song X; Wang J; Yang J
Cancer Chemother Pharmacol; 2012 Dec; 70(6):801-9. PubMed ID: 22996635
[TBL] [Abstract][Full Text] [Related]
47. MicroRNA-7 regulates glioblastoma cell invasion via targeting focal adhesion kinase expression.
Wu DG; Wang YY; Fan LG; Luo H; Han B; Sun LH; Wang XF; Zhang JX; Cao L; Wang XR; You YP; Liu N
Chin Med J (Engl); 2011 Sep; 124(17):2616-21. PubMed ID: 22040413
[TBL] [Abstract][Full Text] [Related]
48. Mucin production determines sensitivity to bortezomib and gemcitabine in pancreatic cancer cells.
Wissniowski TT; Meister S; Hahn EG; Kalden JR; Voll R; Ocker M
Int J Oncol; 2012 May; 40(5):1581-9. PubMed ID: 22266985
[TBL] [Abstract][Full Text] [Related]
49. Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma.
Sunwoo JB; Chen Z; Dong G; Yeh N; Crowl Bancroft C; Sausville E; Adams J; Elliott P; Van Waes C
Clin Cancer Res; 2001 May; 7(5):1419-28. PubMed ID: 11350913
[TBL] [Abstract][Full Text] [Related]
50. CIP2A-mediated Akt activation plays a role in bortezomib-induced apoptosis in head and neck squamous cell carcinoma cells.
Lin YC; Chen KC; Chen CC; Cheng AL; Chen KF
Oral Oncol; 2012 Jul; 48(7):585-93. PubMed ID: 22342571
[TBL] [Abstract][Full Text] [Related]
51. Proteasome inhibition sensitizes non-small-cell lung cancer to gemcitabine-induced apoptosis.
Denlinger CE; Rundall BK; Keller MD; Jones DR
Ann Thorac Surg; 2004 Oct; 78(4):1207-14; discussion 1207-14. PubMed ID: 15464472
[TBL] [Abstract][Full Text] [Related]
52. Bik/NBK accumulation correlates with apoptosis-induction by bortezomib (PS-341, Velcade) and other proteasome inhibitors.
Zhu H; Zhang L; Dong F; Guo W; Wu S; Teraishi F; Davis JJ; Chiao PJ; Fang B
Oncogene; 2005 Jul; 24(31):4993-9. PubMed ID: 15824729
[TBL] [Abstract][Full Text] [Related]
53. Bortezomib inhibits expression of TGF-β1, IL-10, and CXCR4, resulting in decreased survival and migration of cutaneous T cell lymphoma cells.
Chang TP; Poltoratsky V; Vancurova I
J Immunol; 2015 Mar; 194(6):2942-53. PubMed ID: 25681335
[TBL] [Abstract][Full Text] [Related]
54. The proteasome inhibitor bortezomib reverses P-glycoprotein-mediated leukemia multi-drug resistance through the NF-kappaB pathway.
Wang H; Wang X; Li Y; Liao A; Fu B; Pan H; Liu Z; Yang W
Pharmazie; 2012 Feb; 67(2):187-92. PubMed ID: 22512091
[TBL] [Abstract][Full Text] [Related]
55. The bortezomib-induced mitochondrial damage is mediated by accumulation of active protein kinase C-delta.
Durrant D; Liu J; Yang HS; Lee RM
Biochem Biophys Res Commun; 2004 Sep; 321(4):905-8. PubMed ID: 15358112
[TBL] [Abstract][Full Text] [Related]
56. Heparin plays a key regulatory role via a p53/FAK-dependent signaling in melanoma cell adhesion and migration.
Chalkiadaki G; Nikitovic D; Berdiaki A; Katonis P; Karamanos NK; Tzanakakis GN
IUBMB Life; 2011 Feb; 63(2):109-19. PubMed ID: 21360640
[TBL] [Abstract][Full Text] [Related]
57. Proteasome inhibition as a novel mechanism of the proapoptotic activity of γ-secretase inhibitor I in cutaneous T-cell lymphoma.
Biskup E; Kamstrup MR; Manfé V; Gniadecki R
Br J Dermatol; 2013 Mar; 168(3):504-12. PubMed ID: 23445313
[TBL] [Abstract][Full Text] [Related]
58. Bortezomib induces apoptosis of endometrial cancer cells through microRNA-17-5p by targeting p21.
Shen Y; Lu L; Xu J; Meng W; Qing Y; Liu Y; Zhang B; Hu H
Cell Biol Int; 2013 Oct; 37(10):1114-21. PubMed ID: 23716467
[TBL] [Abstract][Full Text] [Related]
59. Proteasome inhibitor bortezomib targeted tumor-endothelial cell interaction in T-cell leukemia/lymphoma.
Shi WY; Wang L; Xiao D; Yao Y; Yang F; Jiang XX; Leboeuf C; Janin A; Chen SJ; Zhao WL
Ann Hematol; 2011 Jan; 90(1):53-8. PubMed ID: 20617436
[TBL] [Abstract][Full Text] [Related]
60. Sorafenib inhibits cell migration and stroma-mediated bortezomib resistance by interfering B-cell receptor signaling and protein translation in mantle cell lymphoma.
Xargay-Torrent S; López-Guerra M; Montraveta A; Saborit-Villarroya I; Rosich L; Navarro A; Pérez-Galán P; Roué G; Campo E; Colomer D
Clin Cancer Res; 2013 Feb; 19(3):586-97. PubMed ID: 23231952
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
